{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:35:41Z","timestamp":1790760941525,"version":"4.1.0"},"reference-count":69,"publisher":"American Association for Cancer Research (AACR)","issue":"10","funder":[{"name":"Dutch Cancer Foundation (KWF)\/Alpe d\u2019HuZes Foundation","award":["UU 2015-7663"],"award-info":[{"award-number":["UU 2015-7663"]}]},{"name":"Dutch Cancer Foundation (KWF)\/Alpe d\u2019HuZes Foundation","award":["11108"],"award-info":[{"award-number":["11108"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Multiple myeloma (MM) is a treatable, but incurable, malignancy of plasma cells (PC) in the bone marrow (BM). It represents the final stage in a continuum of PC dyscrasias and is consistently preceded by a premalignant phase termed monoclonal gammopathy of undetermined significance (MGUS). The existence of this well-defined premalignant phase provides the opportunity to study clonal evolution of a premalignant condition into overt cancer. Unraveling the mechanisms of malignant transformation of PC could enable early identification of MGUS patients at high risk of progression and may point to novel therapeutic targets, thereby possibly delaying or preventing malignant transformation. The MGUS-to-MM progression requires multiple genomic events and the establishment of a permissive BM microenvironment, although it is generally not clear if the various microenvironmental events are causes or consequences of disease progression. Advances in gene-sequencing techniques and the use of serial paired analyses have allowed for a more specific identification of driver lesions. The challenge in cancer biology is to identify and target those lesions that confer selective advantage and thereby drive evolution of a premalignant clone. Here, we review recent advances in the understanding of malignant transformation of MGUS to MM. Cancer Res; 78(10); 2449\u201356. \u00a92018 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-17-3115","type":"journal-article","created":{"date-parts":[[2018,4,27]],"date-time":"2018-04-27T19:20:15Z","timestamp":1524856815000},"page":"2449-2456","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells"],"prefix":"10.1158","volume":"78","author":[{"given":"Niels","family":"van Nieuwenhuijzen","sequence":"first","affiliation":[{"name":"1Laboratory of Translational Immunology, University Medical Center, Utrecht, the Netherlands."},{"name":"2Department of Hematology, University Medical Center, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Spaan","sequence":"additional","affiliation":[{"name":"1Laboratory of Translational Immunology, University Medical Center, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinier","family":"Raymakers","sequence":"additional","affiliation":[{"name":"2Department of Hematology, University Medical Center, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Peperzak","sequence":"additional","affiliation":[{"name":"1Laboratory of Translational Immunology, University Medical Center, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2018,5,14]]},"reference":[{"key":"2022061706173642400_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2022061706173642400_bib2","volume-title":"SEER cancer statistics review, 1975\u20132013","author":"Howlader","year":"2016"},{"key":"2022061706173642400_bib3","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"2022061706173642400_bib4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrc.2017.63","article-title":"Evolutionary biology of high-risk multiple myeloma","volume":"17","author":"Pawlyn","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"2022061706173642400_bib5","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"2022061706173642400_bib6","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"key":"2022061706173642400_bib7","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1158\/1541-7786.MCR-17-0070","article-title":"Intratumor heterogeneity: novel approaches for resolving genomic architecture and clonal evolution","volume":"15","author":"Gupta","year":"2017","journal-title":"Mol Cancer Res"},{"key":"2022061706173642400_bib8","first-page":"389","article-title":"Colorectal Adenomas","volume":"375","author":"Strum","year":"2016","journal-title":"N Engl J Med"},{"key":"2022061706173642400_bib9","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/sj.leu.2401041","article-title":"Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases","volume":"12","author":"Smadja","year":"1998","journal-title":"Leukemia"},{"key":"2022061706173642400_bib10","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1182\/blood-2003-02-0493","article-title":"The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma","volume":"102","author":"Fonseca","year":"2003","journal-title":"Blood"},{"key":"2022061706173642400_bib11","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1038\/bcj.2015.92","article-title":"Interpretation of cytogenetic results in multiple myeloma for clinical practice","volume":"5","author":"Rajan","year":"2015","journal-title":"Blood Cancer J"},{"key":"2022061706173642400_bib12","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","article-title":"Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma","volume":"106","author":"Bergsagel","year":"2005","journal-title":"Blood"},{"key":"2022061706173642400_bib13","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ajh.24094","article-title":"Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management","volume":"90","author":"Vose","year":"2015","journal-title":"Am J Hematol"},{"key":"2022061706173642400_bib14","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nrc3090","article-title":"Cyclin D as a therapeutic target in cancer","volume":"11","author":"Musgrove","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"2022061706173642400_bib15","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","article-title":"Clonal evolution in cancer","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"key":"2022061706173642400_bib16","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.celrep.2017.03.025","article-title":"The mutational landscape of circulating tumor cells in multiple myeloma","volume":"19","author":"Mishima","year":"2017","journal-title":"Cell Rep"},{"key":"2022061706173642400_bib17","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature"},{"key":"2022061706173642400_bib18","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/ejh.12774","article-title":"Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance","volume":"97","author":"Mikulasova","year":"2016","journal-title":"Eur J Haematol"},{"key":"2022061706173642400_bib19","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1038\/leu.2014.59","article-title":"Serial exome analysis of disease progression in premalignant gammopathies","volume":"28","author":"Zhao","year":"2014","journal-title":"Leukemia"},{"key":"2022061706173642400_bib20","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N Engl J Med"},{"key":"2022061706173642400_bib21","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"2022061706173642400_bib22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.bcmd.2014.05.006","article-title":"Quantitative analysis of CKS1B mRNA expression and copy number gain in patients with plasma cell disorders","volume":"53","author":"Stella","year":"2014","journal-title":"Blood Cells Mol Dis"},{"key":"2022061706173642400_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ccell.2017.05.011","article-title":"ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma","volume":"32","author":"Marchesini","year":"2017","journal-title":"Cancer Cell"},{"key":"2022061706173642400_bib24","doi-asserted-by":"crossref","first-page":"7776","DOI":"10.1158\/1078-0432.CCR-11-1791","article-title":"Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival","volume":"17","author":"Boyd","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2022061706173642400_bib25","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1158\/1078-0432.CCR-08-0347","article-title":"Deletions of CDKN2C in multiple myeloma: biological and clinical implications","volume":"14","author":"Leone","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022061706173642400_bib26","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3324\/haematol.2009.011064","article-title":"Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context","volume":"94","author":"Chiecchio","year":"2009","journal-title":"Haematologica"},{"key":"2022061706173642400_bib27","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrc2399","article-title":"Cellular mechanisms of tumour suppression by the retinoblastoma gene","volume":"8","author":"Burkhart","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"2022061706173642400_bib28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.exphem.2015.11.006","article-title":"Deletion of Rb1 induces both hyperproliferation and cell death in murine germinal center B cells","volume":"44","author":"He","year":"2016","journal-title":"Exp Hematol"},{"key":"2022061706173642400_bib29","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejca.2017.06.023","article-title":"Mutant p53 as a target for cancer treatment","volume":"83","author":"Duffy","year":"2017","journal-title":"Eur J Cancer"},{"key":"2022061706173642400_bib30","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3324\/haematol.2010.023697","article-title":"Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma","volume":"95","author":"Lod\u00e9","year":"2010","journal-title":"Haematologica"},{"key":"2022061706173642400_bib31","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"2022061706173642400_bib32","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)","volume":"123","author":"Dhodapkar","year":"2014","journal-title":"Blood"},{"key":"2022061706173642400_bib33","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1182\/blood-2003-01-0016","article-title":"Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis","volume":"102","author":"Davies","year":"2003","journal-title":"Blood"},{"key":"2022061706173642400_bib34","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/leu.2013.199","article-title":"Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms","volume":"28","author":"Walker","year":"2014","journal-title":"Leukemia"},{"key":"2022061706173642400_bib35","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1182\/blood.V128.22.235.235","article-title":"Asymptomatic multiple myeloma - background of progression, evolution, and prognosis","volume":"128","author":"Seckinger","year":"2016","journal-title":"Blood"},{"key":"2022061706173642400_bib36","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3324\/haematol.2017.163766","article-title":"Somatic mutation spectrum in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape compared to multiple myeloma","volume":"102","author":"Mikulasova","year":"2017","journal-title":"Haematologica"},{"key":"2022061706173642400_bib37","doi-asserted-by":"crossref","first-page":"e537","DOI":"10.1038\/bcj.2017.19","article-title":"Mutational landscape reflects the biological continuum of plasma cell dyscrasias","volume":"7","author":"Rossi","year":"2017","journal-title":"Blood Cancer J"},{"key":"2022061706173642400_bib38","first-page":"391","article-title":"Whole exome sequencing of paired MGUS\/SMM to MM patients reveals novel subclonal tumour evolution models in disease progression of multiple myeloma","volume":"130","author":"Dutta","year":"2017","journal-title":"Blood"},{"key":"2022061706173642400_bib39","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1038\/oncsis.2017.36","article-title":"Molecular signaling in multiple myeloma: association of RAS\/RAF mutations and MEK\/ERK pathway activation","volume":"6","author":"Xu","year":"2017","journal-title":"Oncogenesis"},{"key":"2022061706173642400_bib40","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/nrc2231","article-title":"Reflecting on 25 years with MYC","volume":"8","author":"Meyer","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"2022061706173642400_bib41","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/leu.2014.70","article-title":"Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma","volume":"28","author":"Affer","year":"2014","journal-title":"Leukemia"},{"key":"2022061706173642400_bib42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","article-title":"AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies","volume":"13","author":"Chesi","year":"2008","journal-title":"Cancer Cell"},{"key":"2022061706173642400_bib43","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/leu.2016.296","article-title":"The LIN28B\/let-7 axis is a novel therapeutic pathway in multiple myeloma","volume":"31","author":"Manier","year":"2017","journal-title":"Leukemia"},{"key":"2022061706173642400_bib44","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2009-08-237941","article-title":"IL-6 and MYC collaborate in plasma cell tumor formation in mice","volume":"115","author":"Rutsch","year":"2010","journal-title":"Blood"},{"key":"2022061706173642400_bib45","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1476-4598-12-86","article-title":"The complexity of NF-\u03baB signaling in inflammation and cancer","volume":"12","author":"Hoesel","year":"2013","journal-title":"Mol Cancer"},{"key":"2022061706173642400_bib46","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1182\/blood-2009-09-243535","article-title":"Classical and\/or alternative NF-kappaB pathway activation in multiple myeloma","volume":"115","author":"Demchenko","year":"2010","journal-title":"Blood"},{"key":"2022061706173642400_bib47","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1541-7786.MCR-16-0293","article-title":"Combined TRAF6 targeting and proteasome blockade has anti-myeloma and anti-bone resorptive effects","volume":"15","author":"Chen","year":"2017","journal-title":"Mol Cancer Res"},{"key":"2022061706173642400_bib48","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2010-04-279539","article-title":"Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma","volume":"117","author":"Walker","year":"2011","journal-title":"Blood"},{"key":"2022061706173642400_bib49","first-page":"138","article-title":"DNA hypomethylation and human diseases","volume":"1775","author":"Wilson","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"2022061706173642400_bib50","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1038\/bcj.2014.29","article-title":"The role of epigenetics in the biology of multiple myeloma","volume":"4","author":"Dimopoulos","year":"2014","journal-title":"Blood Cancer J"},{"key":"2022061706173642400_bib51","doi-asserted-by":"crossref","first-page":"e52626","DOI":"10.1371\/journal.pone.0052626","article-title":"DNA methylation in multiple myeloma is weakly associated with gene transcription","volume":"7","author":"Jung","year":"2012","journal-title":"PLoS One"},{"key":"2022061706173642400_bib52","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2013-03-487884","article-title":"Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma","volume":"122","author":"Kaiser","year":"2013","journal-title":"Blood"},{"key":"2022061706173642400_bib53","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/ijlh.12504","article-title":"Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"38","author":"van de Donk","year":"2016","journal-title":"Int J Lab Hematol"},{"key":"2022061706173642400_bib54","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"key":"2022061706173642400_bib55","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4065\/82.4.428","article-title":"Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size","volume":"82","author":"Rosi\u00f1ol","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"2022061706173642400_bib56","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"2022061706173642400_bib57","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2141.2009.07929.x","article-title":"Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells","volume":"148","author":"P\u00e9rez-Persona","year":"2010","journal-title":"Br J Haematol"},{"key":"2022061706173642400_bib58","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"2022061706173642400_bib59","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1038\/leu.2017.102","article-title":"Proteomic characterization of human multiple myeloma bone marrow extracellular matrix","volume":"31","author":"Glavey","year":"2017","journal-title":"Leukemia"},{"key":"2022061706173642400_bib60","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","article-title":"Pathogenesis beyond the cancer clone(s) in multiple myeloma","volume":"125","author":"Bianchi","year":"2015","journal-title":"Blood"},{"key":"2022061706173642400_bib61","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrclinonc.2017.197","article-title":"The bone-marrow niche in MDS and MGUS: implications for AML and MM","volume":"15","author":"Ghobrial","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2022061706173642400_bib62","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/nm.4202","article-title":"Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice","volume":"22","author":"Das","year":"2016","journal-title":"Nat Med"},{"key":"2022061706173642400_bib63","doi-asserted-by":"crossref","first-page":"8983","DOI":"10.1038\/ncomms9983","article-title":"Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche","volume":"6","author":"Lawson","year":"2015","journal-title":"Nat Commun"},{"key":"2022061706173642400_bib64","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/leu.2016.3","article-title":"Targeting vasculogenesis to prevent progression in multiple myeloma","volume":"30","author":"Moschetta","year":"2016","journal-title":"Leukemia"},{"key":"2022061706173642400_bib65","doi-asserted-by":"crossref","first-page":"5369","DOI":"10.1158\/1078-0432.CCR-09-0040","article-title":"Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma","volume":"15","author":"Ria","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2022061706173642400_bib66","first-page":"2210","article-title":"Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis","volume":"8","author":"Rajkumar","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2022061706173642400_bib67","doi-asserted-by":"crossref","first-page":"e1008850","DOI":"10.1080\/2162402X.2015.1008850","article-title":"Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma","volume":"4","author":"Calcinotto","year":"2015","journal-title":"Oncoimmunology"},{"key":"2022061706173642400_bib68","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/biomedicines5020034","article-title":"The role of angiogenesis in cancer treatment","volume":"5","author":"Rajabi","year":"2017","journal-title":"Biomedicines"},{"key":"2022061706173642400_bib69","volume-title":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT03236428, Phase II study of the CD38 antibody daratumumab in patients with high-risk MGUS and low-risk smoldering multiple myeloma; 2017. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT03236428"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/78\/10\/2449\/2763473\/2449.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/78\/10\/2449\/2763473\/2449.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T18:07:53Z","timestamp":1655489273000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/78\/10\/2449\/625060\/From-MGUS-to-Multiple-Myeloma-a-Paradigm-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,14]]},"references-count":69,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,5,14]]},"published-print":{"date-parts":[[2018,5,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-17-3115","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,14]]}}}